Compare LFST & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | HAE |
|---|---|---|
| Founded | 2015 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2021 | 1996 |
| Metric | LFST | HAE |
|---|---|---|
| Price | $10.88 | $79.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $9.83 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 3.4M | 566.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | ★ $1,424,285,000.00 | $910,373,000.00 |
| Revenue This Year | $17.18 | N/A |
| Revenue Next Year | $14.02 | $5.23 |
| P/E Ratio | ★ N/A | $38.43 |
| Revenue Growth | ★ 13.85 | N/A |
| 52 Week Low | $3.74 | $47.32 |
| 52 Week High | $11.76 | $87.32 |
| Indicator | LFST | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 66.26 |
| Support Level | $6.23 | $78.87 |
| Resistance Level | $11.69 | $80.60 |
| Average True Range (ATR) | 0.37 | 2.26 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 43.38 | 96.07 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.